Compare Kroger Co (KR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Summit Therapeutics Inc — how do they compare? Kroger Co trades at $57.11 (market cap $35.75B), while Summit Therapeutics Inc trades at $14.41 (market cap $10.48B). The key difference: Kroger Co is far larger — about 3.4× Summit Therapeutics Inc's market cap, and Kroger Co pays a 2.47% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KR | SMMT | |
|---|---|---|
Market Cap | $35.75B | $10.48B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $29.32 |
52-Week Low | $55.53 | $13.05 |
Enterprise Value | $55.85B | $9.90B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $58.39, down 0.73% on the day, with a bearish technical signal and mixed earnings history. The company maintains stable revenue near $147 billion (2025) and recently announced a $1.65 billion acquisition of Giant Eagle (Reuters, July 1, 2026). Cash flow from operations remains strong at $5.79 billion, though net income margin is thin at 0.71%.
Outlook: KR offers value with low P/S (0.25) and dividend yield, but faces margin pressure and integration risks from acquisitions. Analyst consensus is bullish with a $68.63 price target, though technical weakness and competitive threats warrant caution for near-term volatility.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
